{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:15:38Z","timestamp":1763572538390},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s43440-019-00032-x","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T10:02:35Z","timestamp":1579082555000},"page":"456-464","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A new MAP-Rasagiline conjugate reduces \u03b1-synuclein inclusion formation in a cell model"],"prefix":"10.1007","volume":"72","author":[{"given":"Nuno","family":"Vale","sequence":"first","affiliation":[]},{"given":"Cl\u00e1udia","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Vaishali","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Diana F.","family":"L\u00e1zaro","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"32_CR1","doi-asserted-by":"publisher","DOI":"10.1017\/s1462399409001148","author":"T Gasser","year":"2009","unstructured":"Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009. https:\/\/doi.org\/10.1017\/s1462399409001148.","journal-title":"Expert Rev Mol Med"},{"key":"32_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12035-012-8369-3","volume":"42","author":"M Ozansoy","year":"2012","unstructured":"Ozansoy M, Ba\u015fak AN. The central theme of Parkinson\u2019s disease: \u03b1-synuclein. Mol Neurobiol. 2012;42:460\u20135. https:\/\/doi.org\/10.1007\/s12035-012-8369-3.","journal-title":"Mol Neurobiol"},{"key":"32_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/s1353-8020(09)70769-2","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, et al. Neuropathology of non-motor features of Parkinson disease. Park Relat Disord. 2009. https:\/\/doi.org\/10.1016\/s1353-8020(09)70769-2.","journal-title":"Park Relat Disord"},{"key":"32_CR4","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1353-8020(09)70770-9","volume":"15","author":"EC Wolters","year":"2009","unstructured":"Wolters EC. Non-motor extranigral signs and symptoms in Parkinson\u2019s disease. Park Relat Disord. 2009;15:S6\u201312. https:\/\/doi.org\/10.1016\/S1353-8020(09)70770-9.","journal-title":"Park Relat Disord"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1086\/281267","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879\u201384. https:\/\/doi.org\/10.1086\/281267.","journal-title":"Am J Pathol"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340. https:\/\/doi.org\/10.1038\/42166.","journal-title":"Nature"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/nn.4641","volume":"20","author":"DE Mor","year":"2017","unstructured":"Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Daniels MJ, et al. Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci. 2017;20:1560\u20138. https:\/\/doi.org\/10.1038\/nn.4641.","journal-title":"Nat Neurosci"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-007-0302-x","volume":"115","author":"PJ Kahle","year":"2008","unstructured":"Kahle PJ. Alpha-synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:87\u201395. https:\/\/doi.org\/10.1007\/s00401-007-0302-x.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"32_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/hmg\/ddy326","volume":"28","author":"R Pinho","year":"2019","unstructured":"Pinho R, Paiva I, Jercic KG, Fonseca-Ornelas L, Gerhardt E, Fahlbusch C, Garcia-Esparcia P, et al. Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Hum Mol Genet. 2019;28(1):31\u201350. https:\/\/doi.org\/10.1093\/hmg\/ddy326.","journal-title":"Hum Mol Genet"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1673-5374(07)60053-X","volume":"2","author":"H Liu","year":"2007","unstructured":"Liu H, Wang X. Alpha-synuclein and Parkinson disease. Neural Regen Res. 2007;2:239\u201343. https:\/\/doi.org\/10.1016\/S1673-5374(07)60053-X.","journal-title":"Neural Regen Res"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L. Alpha-synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:1\u201323. https:\/\/doi.org\/10.1101\/cshperspect.a009399.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"32_CR12","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","volume":"29","author":"CY Chung","year":"2009","unstructured":"Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV-synucleinopathy. J Neurosci. 2009;29:3365\u201373. https:\/\/doi.org\/10.1523\/JNEUROSCI.5427-08.2009.","journal-title":"J Neurosci"},{"key":"32_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-2004-6412","volume":"6","author":"MA Alim","year":"2004","unstructured":"Alim MA, Ma Q-L, Takeda K, Aizawa T, Matsubara M, Nakamura V, et al. Demonstration of a role for \u03b1-synuclein as a functional microtubule-associated protein. J Alzheimer\u2019s Dis. 2004;6:435\u201342. https:\/\/doi.org\/10.3233\/JAD-2004-6412.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"32_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636\u201340. https:\/\/doi.org\/10.1126\/science.1082324.","journal-title":"Science"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/emboj.2010.223","volume":"29","author":"F Kamp","year":"2010","unstructured":"Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, et al. Inhibition of mitochondrial fusion by \u03b1-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010;29:3571\u201389. https:\/\/doi.org\/10.1038\/emboj.2010.223.","journal-title":"EMBO J"},{"key":"32_CR16","doi-asserted-by":"publisher","first-page":"201713969","DOI":"10.1073\/pnas.1713969114","volume":"114","author":"SS Kang","year":"2017","unstructured":"Kang SS, Zhang Z, Liu X, Manfredsson FP, Benskey MJ, Cao X, et al. TrkB neurotrophic activities are blocked by \u03b1-synuclein, triggering dopaminergic cell death in Parkinson\u2019s disease. Proc Natl Acad Sci. 2017;114:201713969. https:\/\/doi.org\/10.1073\/pnas.1713969114.","journal-title":"Proc Natl Acad Sci"},{"key":"32_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004741","author":"DF L\u00e1zaro","year":"2014","unstructured":"L\u00e1zaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014. https:\/\/doi.org\/10.1371\/journal.pgen.1004741.","journal-title":"PLoS Genet"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1586\/14737175.3.6.737","volume":"3","author":"MBH Youdim","year":"2003","unstructured":"Youdim MBH. Rasagiline: an anti-Parkinson drug with neuroprotective activity. Expert Rev Neurother. 2003;3:737\u201349. https:\/\/doi.org\/10.1586\/14737175.3.6.737.","journal-title":"Expert Rev Neurother"},{"key":"32_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/00001756-199803090-00026","volume":"9","author":"JP Finberg","year":"1998","unstructured":"Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. NeuroReport. 1998;9:703\u20137.","journal-title":"NeuroReport"},{"key":"32_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5041\/RMMJ","volume":"1","author":"JPM Finberg","year":"2010","unstructured":"Finberg JPM. Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson\u2019s disease with neuroprotective potential. Rambam Maimonides Med J. 2010;1:1\u201310. https:\/\/doi.org\/10.5041\/RMMJ.","journal-title":"Rambam Maimonides Med J"},{"key":"32_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","volume":"23","author":"JM Rabey","year":"2000","unstructured":"Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324\u201330. https:\/\/doi.org\/10.1097\/00002826-200011000-00005.","journal-title":"Clin Neuropharmacol"},{"key":"32_CR22","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1517\/14656566.2015.1086748","volume":"16","author":"F Stocchi","year":"2015","unstructured":"Stocchi F, Fossati C, Torti M. Rasagiline for the treatment of Parkinson\u2019s disease: an update. Expert Opin Pharmacother. 2015;16:2231\u201341. https:\/\/doi.org\/10.1517\/14656566.2015.1086748.","journal-title":"Expert Opin Pharmacother"},{"key":"32_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","volume":"92","author":"O Weinreb","year":"2010","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MBH. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010;92:330\u201344. https:\/\/doi.org\/10.1016\/j.pneurobio.2010.06.008.","journal-title":"Prog Neurobiol"},{"key":"32_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/cn5002914","volume":"6","author":"J Kakish","year":"2015","unstructured":"Kakish J, Tavassoly O, Lee JS. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to \u03b1-synuclein. ACS Chem Neurosci. 2015;6:347\u201355. https:\/\/doi.org\/10.1021\/cn5002914.","journal-title":"ACS Chem Neurosci"},{"key":"32_CR25","doi-asserted-by":"publisher","first-page":"e98878","DOI":"10.15252\/embj.201798878","volume":"37","author":"SS Kang","year":"2018","unstructured":"Kang SS, Ahn EH, Zhang Z, Liu X, Manfredsson FP, Sandoval IM, et al. \u03b1-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson\u2019s disease. EMBO J. 2018;37:e98878. https:\/\/doi.org\/10.15252\/embj.201798878.","journal-title":"EMBO J"},{"key":"32_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406\u201324. https:\/\/doi.org\/10.1016\/j.tips.2017.01.003.","journal-title":"Trends Pharmacol Sci"},{"key":"32_CR27","doi-asserted-by":"publisher","first-page":"32301","DOI":"10.1038\/srep32301","volume":"6","author":"P L\u00f6nn","year":"2016","unstructured":"L\u00f6nn P, Kacsinta AD, Cui XS, Hamil AS, Kaulich M, Gogoi K, Dowdy SF. Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. Sci Rep. 2016;6:32301. https:\/\/doi.org\/10.1038\/srep32301.","journal-title":"Sci Rep"},{"key":"32_CR28","doi-asserted-by":"publisher","first-page":"9398","DOI":"10.1038\/s41598-019-45830-8","volume":"9","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Huang YW, Chiou SH, Aronstam RS. Polyhistidine facilitates direct membrane translocation of cell-penetrating peptides into cells. Sci Rep. 2019;9:9398. https:\/\/doi.org\/10.1038\/s41598-019-45830-8.","journal-title":"Sci Rep"},{"key":"32_CR29","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1002\/jps.24186","volume":"103","author":"T Zong","year":"2014","unstructured":"Zong T, Mei L, Gao H, Shi K, Chen J, Wang Y, Zhang Q, Yang Y, He Q. Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT. J Pharm Sci. 2014;103:3891\u2013901. https:\/\/doi.org\/10.1002\/jps.24186(Epub 2014 Oct 22).","journal-title":"J Pharm Sci"},{"key":"32_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2016.01.014","volume":"500","author":"A Srimanee","year":"2016","unstructured":"Srimanee A, Regberg J, Hallbrink M, Vajragupta O, Langel U. Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model. Int J Pharm. 2016;500:128\u201335. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.01.014.","journal-title":"Int J Pharm"},{"key":"32_CR31","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.bmcl.2017.04.086","volume":"27","author":"N Vale","year":"2017","unstructured":"Vale N, Ferreira A, Fernandes I, Alves C, Ara\u00fajo MJ, Mateus N, Gomes P. Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides. Bioorg Med Chem Lett. 2017;27:2898\u2013901. https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.086.","journal-title":"Bioorg Med Chem Lett"},{"key":"32_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1248\/bpb.b17-00848","volume":"41","author":"N Kamei","year":"2018","unstructured":"Kamei N, Yamaoka A, Fukuyama Y, Itokazu R, Takeda-Morishita M. Noncovalent strategy with cell-penetrating peptides to facilitate the brain delivery of insulin through the blood-brain barrier. Biol Pharm Bull. 2018;41:546\u201354. https:\/\/doi.org\/10.1248\/bpb.b17-00848.","journal-title":"Biol Pharm Bull"},{"key":"32_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0005-2736(01)00398-4","volume":"1515","author":"M H\u00e4llbrink","year":"2001","unstructured":"H\u00e4llbrink M, Flor\u00e9n A, Elmquist A, Pooga M, Bartfai T, Langel \u00dc. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta Biomembr. 2001;1515:101\u20139. https:\/\/doi.org\/10.1016\/S0005-2736(01)00398-4.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"32_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0005-2736(98)00161-8","volume":"1414","author":"J Oehlke","year":"1998","unstructured":"Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, et al. Cellular uptake of an \u03b1-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta Biomembr. 1998;1414:127\u201339. https:\/\/doi.org\/10.1016\/S0005-2736(98)00161-8.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"32_CR35","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/j.1432-1033.2004.04236.x","volume":"271","author":"J Oehlke","year":"2004","unstructured":"Oehlke J, Wallukat G, Wolf Y, Ehrlich A, Wiesner B, Berger H, et al. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur J Biochem. 2004;271:3043\u20139. https:\/\/doi.org\/10.1111\/j.1432-1033.2004.04236.x.","journal-title":"Eur J Biochem"},{"key":"32_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1476-5381.2008.00057.x","volume":"157","author":"F Heitz","year":"2009","unstructured":"Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157:195\u2013206. https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00057.x.","journal-title":"Br J Pharmacol"},{"key":"32_CR37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1021\/mp200615m","volume":"9","author":"IG Zigoneanu","year":"2012","unstructured":"Zigoneanu IG, Pielak GJ. Interaction of \u03b1-synuclein and a cell penetrating fusion peptide with higher eukaryotic cell membranes assessed by 19F NMR. Mol Pharm. 2012;9:1024\u20139. https:\/\/doi.org\/10.1021\/mp200615m.","journal-title":"Mol Pharm"},{"key":"32_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1471-4159.2007.05204.x","volume":"105","author":"F Nagel","year":"2008","unstructured":"Nagel F, Falkenburger BH, T\u00f6nges L, Kowsky S, P\u00f6ppelmeyer C, Schulz JB, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson\u2019s disease. J Neurochem. 2008;105:853\u201364. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05204.x.","journal-title":"J Neurochem"},{"key":"32_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.molmed.2004.03.008","volume":"10","author":"T Borsello","year":"2004","unstructured":"Borsello T, Bonny C. Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol Med. 2004;10:239\u201344. https:\/\/doi.org\/10.1016\/j.molmed.2004.03.008.","journal-title":"Trends Mol Med"},{"issue":"1","key":"32_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40478-016-0402-8","volume":"4","author":"DF L\u00e1zaro","year":"2016","unstructured":"L\u00e1zaro DF, Dias MC, Carija A, Navarro S, Madaleno CS, Tenreiro S, et al. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. Acta Neuropathol Commun. 2016;4(1):128.","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"32_CR41","doi-asserted-by":"publisher","first-page":"e1004741","DOI":"10.1371\/journal.pgen.1004741","volume":"10","author":"DF L\u00e1zaro","year":"2014","unstructured":"L\u00e1zaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014;10(11):e1004741. https:\/\/doi.org\/10.1371\/journal.pgen.1004741.","journal-title":"PLoS Genet"},{"issue":"4","key":"32_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/1061186X.2011.649481","volume":"20","author":"R Kenien","year":"2012","unstructured":"Kenien R, Zaro JL, Shen W-C. MAP-mediated nuclear delivery of a cargo protein. J Drug Target. 2012;20(4):329\u201337. https:\/\/doi.org\/10.3109\/1061186X.2011.649481.","journal-title":"J Drug Target"},{"key":"32_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbiomech.2018.03.036","volume":"73","author":"G Grasso","year":"2018","unstructured":"Grasso G, Muscat S, Rebella M, Morbiducci U, Audenino A, Danani A, Deriu MA. Cell penetrating peptide modulation of membrane biomechanics by molecular dynamics. J Biomech. 2018;73:137\u201344. https:\/\/doi.org\/10.1016\/j.jbiomech.2018.03.036.","journal-title":"J Biomech"},{"issue":"3","key":"32_CR44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbamem.2006.01.006","volume":"1758","author":"S Pujals","year":"2006","unstructured":"Pujals S, Fern\u00e1ndez-Carneado J, L\u00f3pez-Iglesias C, Kogan MJ, Giralt E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta. 2006;1758(3):264\u201379. https:\/\/doi.org\/10.1016\/j.bbamem.2006.01.006(PMID: 16545772).","journal-title":"Biochim Biophys Acta"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00032-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-019-00032-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00032-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T07:18:12Z","timestamp":1610608692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-019-00032-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s43440-019-00032-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}